Q-omics provides the consensus-scored PCDH9-AS2 profile across patient tissues and cancer cell-line models. PCDH9-AS2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PCDH9-AS2 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, PCDH9-AS2 RNA expression shows 6,466 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, LIHC, and GBM as cancer lineages where PCDH9-AS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDH9-AS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDH9-AS2 survival associations across molecular data types. PCDH9-AS2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDH9-AS2 RNA expression–survival associations across cancer types. High PCDH9-AS2 expression shows unfavorable associations in LUAD, ACC, KIRP, READ and SARC, but favorable associations in MESO. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PCDH9-AS2 RNA expression.
This table summarizes PCDH9-AS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDH9-AS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDH9-AS2 shows lower tumor expression in LIHC, KIRC, CHOL and STAD. The LIHC box plot shows higher PCDH9-AS2 RNA expression in normal versus tumor tissue (log2 FC = −1.171, t-test p < 0.001).
This table shows molecular features associated with PCDH9-AS2 in patient tissues and cancer cell lines. In patient samples, PCDH9-AS2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
